Your session is about to expire
← Back to Search
Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia
Study Summary
This trial studies a targeted cancer cell killing monoclonal antibody in patients with B-cell acute lymphocytic leukemia who have positive minimal residual disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 trial • 72 Patients • NCT01363297Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had monoclonal antibody therapy in the last 2 weeks.I haven't had major cancer treatment or experimental drugs in the last 2 weeks.My ALL is in remission but still shows signs of cancer cells.I have Philadelphia chromosome-positive ALL and am in my first or second complete remission.I do not have another cancer that could shorten my life within a year.My doctor thinks I have an active and uncontrolled disease or infection.I can take care of myself and perform daily activities.My cancer has spread to my brain or nervous system.I cannot or do not want to sign the consent form.I have B-lineage ALL, in remission but with minimal disease after treatment, including after a stem cell transplant.
- Group 1: Treatment (inotuzumab ozogamicin)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the Inotuzumab Ozogamicin FDA rating?
"Inotuzumab Ozogamicin's safety is supported by some data, but because this is only a Phase 2 trial, there is no indication of efficacy yet. It received a score of 2 from our team."
How many people can join this trial at most?
"That is correct. The listing on clinicaltrials.gov says that the study is still recruiting patients. It was first posted on February 15th, 2018 and was updated September 22nd, 2020. Currently, 40 people are needed for the trial taking place at 1 location."
Is this the only time Inotuzumab Ozogamicin has been put through a clinical trial?
"There are currently 17 ongoing clinical trials researching Inotuzumab Ozogamicin. 2 of those are Phase 3 studies. The majority of these medical research projects are being conducted in Boston, Massachusetts; however, there 856 total sites running these sorts of tests."
Are there any remaining vacancies for participants in this experiment?
"That is accurate. The clinicaltrials.gov website notes that this trial, which was initially publicized on February 15th 2018, is still recruiting patients. Currently, the plan is to enroll 40 people from a single location."
Share this study with friends
Copy Link
Messenger